Island Disease

People living on islands in the Norwegian Sea suffer from an unusually high rate of certain genetic diseases and health issues, making the population ripe for research.

Aug 1, 2012
Jef Akst

In 1993, recent med-school grad Ulrike Steuerwald traveled to the Faroe Islands between Norway and Iceland to play violin as part of an orchestra. Once there, she learned that the Islands’ only pediatrician was on sabbatical, leaving the local population with only nonspecialists to care for children.

Having just finished her training in pediatrics, Steuerwald promptly accepted an offer to fill in for the traveling pediatrician. “You can learn as much in 1 year as a pediatrician in the Faroe Islands as you would learn in 10 years in another place,” she says. And more importantly, the nearest pediatrician was in Copenhagen—“1,200 kilometers away,” she says. The families on the islands needed her help.

She moved to the Faroes in November, and stayed for 5 years, working full time at the central hospital in the capital city of Tórshavn. During that time, she saw several patients who suffered from glycogen storage disease type III (GSD III), a genetic disorder that can cause extreme hypoglycemia. Via a mutation disabling a key enzyme, the disease prevents the proper processing of stored sugar in the liver, which normally releases the sugar into the bloodstream as glucose, as well as in skeletal and heart muscle, where normal function depends on the quick availability of glucose as fuel. While GSD III is a manageable disease, it is also extremely rare, affecting just 1 in 300,000 people in the United States. “GSD may get 10 or 20 minutes in medical school, and there’s no way a doctor’s going to be an expert on this, or even remember anything years later,” says David Weinstein, director of the Glycogen Storage Disease Program at the University of Florida College of Medicine.


TESTING KIDS: Ulrike Steuerwald examines a Faroese child.
Credit: Fróði Debes


As a result, many children with GSD do not always receive the basic dietary treatments that can manage their symptoms. The Faroes, where GSD III occurs once in every 3,000 people, was one place where the disease was not well controlled. The islands, now part of the Kingdom of Denmark, were settled more than 1,000 years ago by Vikings, some of whom likely passed on the recessive mutation conferring inability to process sugar to their descendants. But neither Steuerwald nor the Danish doctors to whom she referred severe cases knew much about the disease, and the Faroese children continued to suffer severe symptoms as stored sugar accumulated in their livers and muscles. One girl Steuerwald remembers well was told she’d need a new heart.

Nearly 10 years later, after Steuerwald had begun splitting her time between the Faroes and Hannover, Germany, where she now works at a neonatal screening lab and in a private pediatric practice, she attended a 3-day workshop devoted completely to GSD. Many families on the Faroes were still struggling with the disease, traveling to Denmark only to return home with more questions. “I went hoping to get some answers for the questions I still had, answers for these parents,” she says.

Steuerwald met David Weinstein, who quickly agreed to help the people of the Faroe Islands. She followed his recommendation to start the children on diets high in protein—about 4 times the amount a person typically eats—and low doses of cornstarch, which is slowly digested and broken down into glucose at a rate that can be used by the body before it’s stored. The kids immediately started to improve. The following year, Weinstein flew out to meet the families, and he is now setting up a new research center on the Faroes in partnership with the country’s health minister. “Because they’re in a small area, you tend to be able to follow up for long periods of time,” says Elaine Murphy, a consultant at the National Hospital for Neurology and Neurosurgery in London. “We don’t really always know what happens to people [with GSD] as they get older.”

Weinstein says he’s also hoping to uncover clues that will be relevant to much more common conditions, such as high cholesterol, which is a prevalent problem on the Faroes, despite the fact that the islanders eat naturally high-protein, low-saturated-fat diets of fish, meat, and root vegetables. Weinstein suspects that cholesterol problems among the Faroese are related to the high incidence of GSD III and the fact that one in every 22 people in the country carries a copy of the mutation that causes the disease. Parents or siblings of GSD patients sometimes express mild hypoglycemia and high cholesterol—“all the different things that go along with this disease, just in a milder form,” he says. “It clearly is not totally benign [for carriers] like it’s written in the textbooks.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets


Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.